Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 Million in its first external funding round. The financing round is led by Thrive Capital, with ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is ...

Isomorphic will use the windfall to fund development of its next-generation artificial intelligence drug design model, the company announced in a March 31 release. The AI biotech is also looking ...

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical programs, and accelerate disease research.

Isomorphic was founded in 2021, but it wasn’t until yesterday that the company announced its first external funding—a $600 million round, led by Thrive Capital with participation from GV.

Isomorphic Labs, the London-based, drug discovery–focused spinout of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical ...

NVS Novartis AG $117.70 0.20 % Isomorphic Labs, a London-based spin-out of Alphabet Inc GOOG GOOGL Google's AI R&D division DeepMind, has announced strategic partnerships with Eli Lilly And Co ...

Isomorphic Labs is the secretive AI life sciences startup spun out of Google DeepMind with the goal of solving all disease with AI-powered drug discovery.

Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. LONDON ...

The fledgling company was Isomorphic Labs, the secretive artificial intelligence life sciences startup spun out of Google DeepMind after one of the biggest biological breakthroughs in the last 50 ...